CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved a new intramuscular (IM) injection route of ...

The US Food and Drug Administration (FDA) has approved intramuscular (IM) administration of peginterferon β-1a (Plegridy, Biogen) for patients with relapsing forms of multiple sclerosis (MS). "The new ...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, ...

(RTTNews) - Biogen Inc. (BIIB) said Monday that the U.S. Food and Drug Administration has approved a new intramuscular (IM) injection route of administration for PLEGRIDY (peginterferon beta-1a) for ...

LONDON and SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced headline data from the randomized, ...

The European Commission (EC) has approved a new intramuscular (IM) injection route of administration for Biogen’s Plegridy for the treatment of relapsing-remitting multiple sclerosis (RRMS). Plegridy ...

TOPSHOT - Nurse Practitioner Terri Welch administers a dose of the Pfizer-BioNTech Covid-19 vaccine to a patient at the Haxby and Wigginton Group Medical Practice in Haxby, northern England on ...

Results were announced from a phase 3 study evaluating an investigational intramuscular (IM) formulation of ibalizumab-uiyk for the treatment of heavily treatment-experienced adults with ...